DisProt by Hatos, András et al.
Nucleic Acids Research, 2019 1
doi: 10.1093/nar/gkz975
DisProt: intrinsic protein disorder annotation in 2020
Andra´s Hatos 1, Borba´la Hajdu-Solte´sz2, Alexander M. Monzon1, Nicolas Palopoli3,
Lucı´a ´Alvarez4, Burcu Aykac-Fas5, Claudio Bassot6, Guillermo I. Benı´tez3,
Martina Bevilacqua1, Anastasia Chasapi7, Lucia Chemes4,8, Norman E. Davey9,
Radoslav Davidovic´10, A. Keith Dunker11, Arne Elofsson6, Julien Gobeill12, Nicola´s
S. Gonza´lez Foutel4, Govindarajan Sudha6, Mainak Guharoy13,14, Tamas Horvath15,
Valentin Iglesias16, Andrey V. Kajava17,18, Orsolya P. Kovacs15, John Lamb6,
Matteo Lambrughi5, Tamas Lazar13,14, Jeremy Y. Leclercq17, Emanuela Leonardi19,20,
Sandra Macedo-Ribeiro21, Mauricio Macossay-Castillo13,14, Emiliano Maiani5, Jose´
A. Manso21, Cristina Marino-Buslje22, Elizabeth Martı´nez-Pe´rez22, Ba´lint Me´sza´ros2,
Ivan Micˇetic´1, Giovanni Minervini1, Nikoletta Murvai15, Marco Necci1, Christos
A. Ouzounis7, Ma´tya´s Pajkos2, Lisanna Paladin1, Rita Pancsa15, Elena Papaleo5,23,
Gustavo Parisi3, Emilie Pasche12, Pedro J. Barbosa Pereira21, Vasilis J. Promponas24,
Jordi Pujols16, Federica Quaglia1, Patrick Ruch12, Marco Salvatore6, Eva Schad15,
Beata Szabo15, Tama´s Szaniszlo´2, Stella Tamana24, Agnes Tantos15, Nevena Veljkovic10,
Salvador Ventura16, Wim Vranken13,14,25, Zsuzsanna Doszta´nyi2, Peter Tompa13,14,15, Silvio
C. E. Tosatto1,26,* and Damiano Piovesan1
1Department of Biomedical Sciences, University of Padova, Padova 35121, Italy, 2MTA-ELTE Lendu¨let Bioinformatics
Research Group, Department of Biochemistry, Eo¨tvo¨s Lora´nd University, Budapest 1117, Hungary, 3Departamento
de Ciencia y Tecnologı´a, Universidad Nacional de Quilmes - CONICET, Bernal, Buenos Aires B1876BXD, Argentina,
4Consejo Nacional de Investigaciones Cientı´ficas y Te´cnicas. Instituto de Investigaciones Biotecnolo´gicas IIBIO,
Universidad Nacional de San Martı´n, San Martı´n, Buenos Aires, Argentina, 5Computational Biology Laboratory,
Danish Cancer Society Research Center, Copenhagen DK-2100, Denmark, 6Department of Biochemistry and
Biophysics and Science for Life Laboratory, Stockholm University, Box 1031, Solna 17121, Sweden, 7Biological
Computation & Process Laboratory, Chemical Process & Energy Resources Institute, Centre for Research &
Technology Hellas, Thessalonica GR-57500, Greece, 8Departamento de Fisiologı´a y Biologı´a Molecular y Celular
(DFBMC), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina,
9Division of Cancer Biology, The Institute of Cancer Research, Chelsea, London SW3 6BJ, UK, 10Laboratory for
Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, University of Belgrade,
Belgrade 11001, Serbia, 11Center for Computational Biology and Bioinformatics, Indiana University School of
Medicine, IN 46202, USA, 12Swiss Institute of Bioinformatics and HES-SO \ HEG, Geneva 1200, Switzerland,
13Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels 1050, Belgium, 14VIB-VUB Center for
Structural Biology, Flanders Institute for Biotechnology (VIB), Brussels 1050, Belgium, 15Institute of Enzymology,
Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest H-1117, Hungary, 16Departament
de Bioquı´mica i Biologia Molecular and Institut de Biotecnologia i Biomedicina, Universitat Auto`noma de Barcelona,
Bellaterra 08193, Spain, 17Centre de Recherche en Biologie cellulaire de Montpellier (CRBM), UMR 5237 CNRS,
Universite´ Montpellier, Montpellier 34293, France, 18Institut de Biologie Computationnelle(IBC), Montpellier 34095,
France, 19Department of Woman and Child Health, University of Padova, Padova 35127, Italy, 20Fondazione Istituto
di Ricerca Pediatrica (IRP), Citta` della Speranza, Padova 35127, Italy, 21Instituto de Biologia Molecular e Celular
(IBMC) and Instituto de Investigac¸a˜o e Inovac¸a˜o em Sau´de (i3S), Universidade do Porto, Porto 4200-135, Portugal,
22Bioinformatics Unit. Fundacio´n Instituto Leloir, Ciudad de Buenos Aires C1405BWE, Argentina, 23Translational
Disease Systems Biology, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein
*To whom correspondence should be addressed. Tel: +39 049 827 6269; Email: silvio.tosatto@unipd.it
C© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz975/5622715 by Sem
m
elw
eis U
niversity user on 29 N
ovem
ber 2019
2 Nucleic Acids Research, 2019
Research University of Copenhagen, Copenhagen DK-2200, Denmark, 24Bioinformatics Research Laboratory,
Department of Biological Sciences, University of Cyprus, Nicosia, CY 1678, Cyprus, 25Interuniversity Institute of
Bioinformatics in Brussels (IB2), ULB-VUB, Brussels 1050, Belgium and 26CNR Institute of Neurosceince, Padova
35121, Italy
Received September 15, 2019; Revised October 11, 2019; Editorial Decision October 11, 2019; Accepted October 12, 2019
ABSTRACT
The Database of Protein Disorder (DisProt, URL:
https://disprot.org) provides manually curated anno-
tations of intrinsically disordered proteins from the
literature. Here we report recent developments with
DisProt (version 8), including the doubling of protein
entries, a new disorder ontology, improvements of
the annotation format and a completely new web-
site. The website includes a redesigned graphical
interface, a better search engine, a clearer API for
programmatic access and a new annotation inter-
face that integrates text mining technologies. The
new entry format provides a greater flexibility, sim-
plifies maintenance and allows the capture of more
information from the literature. The new disorder on-
tology has been formalized and made interoperable
by adopting the OWL format, as well as its structure
and term definitions have been improved. The new
annotation interface has made the curation process
faster and more effective. We recently showed that
new DisProt annotations can be effectively used to
train and validate disorder predictors. We believe the
growth of DisProt will accelerate, contributing to the
improvement of function and disorder predictors and
therefore to illuminate the ‘dark’ proteome.
INTRODUCTION
About 20 years ago, the concept of the intrinsic structural
disorder of proteins came into being (1,2). Since then, the
field has reached adulthood, with the concept of protein
disorder gaining wide acceptance in the community. Intrin-
sically disordered proteins/regions (IDPs/IDRs) are now
often being referred to without a citation, the term hav-
ing become as common as the ‘globular’ structure of a
protein, or the ‘active site’ of an enzyme. Yet, the field is
still accelerating and has not reached its climax, as sig-
naled by several recent breakthroughs and high-impact
stories (3,4).
For example, it was recently recognized by ‘omics’ data
analyses that about half of eukaryotic proteins are ‘dark’,
in the sense that we have no information on their 3D struc-
ture (5), which poses a serious bottleneck in their func-
tional characterization and annotation. Similarly, only 45%
of the residues of all human proteins are covered by multi-
ple sequence alignment-based Pfam-A protein family anno-
tations (6). These values suggest that we have only a vague
notion about the structure and function of the majority of
proteins in our databases. As a significant fraction of the
dark proteome and non-Pfam annotated proteins and pro-
tein regions are intrinsically disordered (the concepts hav-
ing become almost synonymous), our best approach for il-
luminating the dark proteome is to predict disorder from
sequence, and experimentally characterize the underlying
structural ensembles (7).
The prediction of protein disorder from sequence was on
the menu of the Critical Assessment of Protein Structure
Prediction (CASP), a community-wide experiment of pre-
dicting protein structures from sequence (8), formany years.
A new initiative, the Critical Assessment of Intrinsic pro-
tein Disorder (CAID), has now reached maturity and will
be reintegrated into the CASP programme, with a clearer
IDP perspective. New annotations in DisProt have already
been used to provide a blind evaluation of disorder predic-
tors (9).
Several recent breakthroughs have also signaled the vi-
tality of the field. An unsettled question with IDPs/IDRs is
whether their structural disorder persits in the crowded inte-
rior of cells.Whereas diverse indirect evidence indicates that
this is the case (10), only in-cell NMR seems currently avail-
able to address this issue. For example, it was recently ap-
plied to study Parkinson’s disease protein -synuclein (Dis-
Prot DP00070), once suggested to have folded, oligomeric
structure in cells (11). In-cell NMR has clearly shown that
-synuclein preserves its disordered, monomeric state in
non-neuronal and neuronal cells alike (12).
Another aspect of the functionality of IDPs is that they
often mediate protein-protein interactions, mostly by fold-
ing upon partner binding (13), but sometimes by preserv-
ing their structural disorder (fuzziness) in the bound state
(14). This was recently shown to occur in the extremely
tight (picomolar) interaction between two human IDPs, hi-
stone H1 (DisProt DP01156) and its nuclear chaperone,
prothymosin- (DisProt DP01677). These proteins asso-
ciate while retaining their highly dynamic, fully disordered
state (15). Functional regulation of another type may also
arise from structural disorder, via the entropic force gen-
erated by the structural ensemble of an IDP/IDR. In the
enzyme UDP--D-glucose-6-dehydrogenase (UGDH, Dis-
Prot DP02338), the C-terminal disordered tail has such a
role, fine-tuning the energy landscape of the protein and sta-
bilizing a sub-state that has a high affinity for an allosteric
inhibitor (16,17).
It is without doubt that we cannot afford to ignore this
intrinsically disordered, yet functionally important part of
the proteome. Not only does structural disorder play an
exquisite role in cellular signaling and regulation (18), it is
also often implicated in disease (19,20). Consequently, IDPs
also represent important drug targets: a largely unexplored
frontier in developingmolecular medicine is the rational de-
sign of drugs against IDPs (21,22).
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Due to these challenges, it is important to update and up-
grade DisProt, the primary database of protein disorder.
Whereas predicted disorder features are available in Mo-
biDB (18), which has recently been integrated in UniPro-
tKB (23), the crux of understanding protein disorder is the
availability ofmanually curated, experimentally verified dis-
order annotations. The previous release of the database,
DisProt 7 (24), held data of ∼800 entries of IDPs/IDRs.
Other databases, like IDEAL (22), ELM (25), DIBS (26)
and MFIB (27), also include curated disorder information
but are somehow different capturing specific functional as-
pects, or protein classes, and the overlap with DisProt is
minimal (28). To reflect on the above-noted breakthroughs
and the recent explosion of the related liquid-liquid phase
separation (LLPS) field (29), we present a significant update
and upgrade of the DisProt database, which is now at ver-
sion 8. DisProt 8 holds almost two-times as many entries as
DisProt 7, including themajority of those available in afore-
mentioned databases.
DisProt has been completely redesignedwith an extended
and updated functional classification scheme that relies on
functional/structural aspects of annotated regions and in-
corporates a novel functional class ‘biological condensa-
tion’. Annotation concepts have been formalized in a new
Disorder Ontology (DO), which is maintained by the entire
DisProt community.
DisProt 8 also has many novel features that make it eas-
ier to search. The graphical interface has been redesigned
and a new entry format provides greater flexibility, simpli-
fies maintenance and allows the capture of more informa-
tion from the literature.
Lastly, we made significant improvements on the new
annotation interface used by DisProt curators to populate
the database. It is now easier to use and leverages cura-
tors’ work by enabling text-mining technologies, integrating
third-party information on-the-fly and implementing sev-
eral validation checks.
In recent work, specific sequence features have been as-
sociated with different disorder ‘flavours’ and mapped on
a large scale (30). This information has been used to im-
prove protein function prediction from sequence (31). We
believe the growth of DisProt will accelerate, contributing
to the improvement of function and disorder predictors and
therefore to illuminate the ‘dark’ proteome.
PROGRESS AND NEW FEATURES
Database structure and implementation
The way disorder information is represented in the litera-
ture is inherently complex. Articles describe functional and
structural aspects, where IDPs are strictly connected to dy-
namic behavior. DisProt tries to capture as much biologi-
cal knowledge as possible while at the same time providing
simple and clear annotations. The idea is to optimize user
experience and improve data exchange with other major an-
notation resources.
Database records
The major change compared to the previous release is
the new annotation paradigm. In DisProt 7, experimen-
tal methods represented the annotation core of a DisProt
region and function terms were used as attributes. Now
the core of an annotation is the functional/structural as-
pect of a region and the experimental method is an at-
tribute representing the quality of the annotation. Both
functional/structural aspects and the type of evidence are
encoded in a controlled vocabulary, in line with other core
data resources (e.g. UniProtKB). In the new DisProt region
format, a ‘statement’ field has been introduced to track the
literature text supporting the evidence. When the text is too
long or complicated, a curator statement is provided in-
stead. All ‘statements’ are available from the website and
could be used to train text-mining algorithms and to high-
light sentence-based annotations on abstracts and full text
articles. A new ‘obsolete’ field has been introduced in order
to track regions which have been excluded from the current
release. It also includes the reason for obsolescence, usu-
ally changes in the reference sequence due to UniProKB
updates or curator errors.
At present, functional terms can be associated to a subset
of disordered residues, i.e. to a region shorter than the one
for which disorder has been experimentally evaluated. For
example, a paper describing a folding upon binding event
can provide two DisProt records, one region spanning the
folding residues and another showing the interacting ones.
All regions have now a region identifier field which is unique
and stable, i.e. it is never reused and becomes obsolete if the
reference sequence changes. Functional and structural vo-
cabulary terms along with experimental methods have been
encoded in a new Disorder Ontology (DO).
Disorder ontology
In order to describe the different functional aspects of IDPs
and the experimental methods used to characterize them,
an annotation scheme was introduced in DisProt 7. A more
formalized version of the disorder ontology was imple-
mented inDisProt 8, tomove towards a descriptive, interop-
erable and collaborative ontology of IDPs. This is the first
release of the Disorder Ontology in the specific Biomedical
Ontology (OBO) or the Web Ontology Language (OWL)
formats (32,33). Besides improving the ability to reuse and
share the ontology, these formats allow definition of la-
bel attributes such as ‘xterm’ (cross-references to external
databases or ontologies) and ‘synonym EXACT’ (alterna-
tive names). They also support assignment of relationships
among terms (including for example ‘disjoint from’ tomark
terms that should not be linked together).
An identifier was assigned to each term in the on-
tology. It gives each label an 8-character accession code
(e.g. ‘DO:00001’), with the string ‘DO:’ to indicate the dis-
order ontology and five numeric characters to indicate the
term unambiguously. Mirroring the Gene Ontology, acces-
sion numbers are assigned incrementally and there is no re-
lationship between accession codes and the ontology topol-
ogy.
Wehave reviewed the terms and organization of thewhole
ontology, paying particular attention to the ‘Function’ cat-
egory. We made some straightforward changes, for exam-
ple, we split ‘Fatty acylation (myristoylation and palmity-
lation)’ into a renamed parent class ‘Fatty acylation’ and
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its new children terms ‘Myristoylation’ and ‘Palmitoyla-
tion’. A new functional term was also introduced to anno-
tate different phenomena related to ‘Biological condensa-
tion’ (DO:00040). It describes proteins that undergo phase
separation from a solution, e.g. either to form a dynamic
liquid droplet (DO:00041, ‘liquid–liquid phase separation’)
or a hydrogel (DO:00042). It also includes cellular protein
condensates (DO:00045 and DO:00046 describe ‘granule’
and ‘cellular puncta’, respectively), regardless of their ex-
istence in physiological or pathological states (as in ‘Amy-
loid’, DO:00046). This class provides an initial scheme to
annotate the relevant but still scarce information available
about protein condensates, and we expect this subset of the
hierarchy to be modified (possibly by conforming its own
sub-ontology) as the field matures.
The distinction between structural states and dynamic
events, like disorder-to-order transitions, has been made
clearer. Previously ‘Structural state’ terms were part of
the ‘structural transition’ category and ‘disorder’ was only
used implicitly. Now, a new ‘structural state’ category has
been created and it includes ‘disorder’, ‘order’, ‘pre-molten
globule’ and ‘molten globule’ terms. In the future, struc-
tural states will be annotated in conjunction with the cor-
responding environmental conditions affecting the confor-
mation (pH, post-translational modifications (PTMs), tem-
perature, etc.).
All experimentalmethods are now encoded under the ‘de-
tection method’ branch. An overlap with other ontologies
exists, but it is not complete or the definition of the same
experiment is often slightly different. For example, in Dis-
Prot the term ‘crystallography’ includes ‘missing electron
density’ as a child. In other ontologies ‘crystallography’ al-
ways indicates methods for structural determination. A new
‘electron cryomicroscopy’ (DO:00128) term has been also
introduced in DisProt 8.
The Disorder Ontology (version 0.1.0) is maintained by
the DisProt consortium and is available to be adopted by
other databases for general use. In the future, it will bemade
available also from third party dedicated repositories.
Curation process and updates
DisProt data is provided by a community effort and annota-
tions are collected through a web interface, which has been
improved drastically compared to the previous version in
terms of field validation, autocompletion and Named En-
tity Recognition (NER). In particular, curators can use a
dedicated service from the NextA5 literature triage infras-
tructure (34) to rank relevant literature starting from a gene
name. In complement, when curators start from an article,
the DisProt interface exploits the SciLite software through
the EuropePMC API (35) to automatically retrieve biolog-
ical entities and identifiers in the manuscript.
The annotation interface implements the concept of own-
ership and user privileges. DisProt distinguishes two types
of users, curators and reviewers. Curators can edit only en-
tries that they have created, while reviewers can modify all
entries. Before release, the reviewers check all annotations
to ensure high quality of the data. Curators are experts in
the field and trained to meet DisProt annotation standards.
As a community database, DisProt looks for new curators.
Curator candidates are enrolled upon an evaluation of the
curriculum and curation skills.
Access to the annotation interface is restricted to regis-
tered curators and provided through Google Authentica-
tion (based on the OAuth 2.0 protocol) or the ELIXIR au-
thentication and authorization infrastructure system (36).
In the past, the DisProt interface had been kept open for
limited time slots. Now the new DisProt interface is always
open and new releases will be delivered more frequently, i.e.
every six months.
DisProt versioning has been improved. A numeric identi-
fier indicates the version of the database entry, e.g., version
‘8.0’ and a ‘<year> <month>’ code indicates the version
(timestamp) of annotated data, e.g. ‘2019 09’.
Database content
Since the last release, both the number of proteins and re-
gions has almost doubled. DisProt 8 contains 1556 pro-
teins and 3511 sequence segments annotated as disordered,
which cover 19.7% of the number of residues. These num-
bers become 1390 proteins, 3041 regions and 18.7% of dis-
order content when ambiguous evidence is not considered.
Previous annotations have been fixed and updated. Regions
shorter than ten residues are no longer allowed and existing
short regions were marked as obsolete as the majority are
flexible loops annotated fromX-ray experiments that do not
represent disorder-related functional sites. Regions ending
outside the sequence, regions with a start index of zero in-
stead of one and entries for which the reference sequence in
UniProtKB changed, were corrected and, when necessary,
new records were created manually.
Figure 1 shows the distribution of regions based on
their length and experimental detection method. Com-
pared to the previous version, the distribution shape has
not changed. Secondary methods, which include all ‘de-
tection methods’ terms except ‘missing electron density’
(DO:00130) and ‘nuclear magnetic resonance’ (DO:00120)
dominate experiments used to identify longer (>100
residues) regions.
The statistics on annotation data for the main branches
of the disorder ontology are reported in Figure 2. Only
terms one node away from the ontology root are considered
and more specific annotations are propagated following the
‘true path rule’, i.e. following the ontology hierarchy, so that
parent terms account for children counts.
Different ontology aspects (‘namespace’ field in DisProt
records), are shown with different colors. In red the ‘struc-
tural state’ terms show as the majority of region records
in DisProt are annotated as disordered. Only five proteins
are annotated with the ‘order’ term. In the future, curators
will be encouraged to also track information about order,
in particular when relevant for structural transitions. Tran-
sitions are mainly covering folding events (‘disorder to or-
der’), 365 proteins and 36 200 residues, and not the contrary.
The majority of interaction partner annotations refers pro-
tein and nucleic acid binding. Binding residues are, how-
ever, overestimated since in the previous DisProt version,
due to hard constraints in the database schema, it was not
possible to narrow region boundaries to real interacting po-
sitions. Binding positions will become more precise in the
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Figure 1. Distribution of region length. Regions shorter than 100 residues (left) are binned in groups of 10 residues. Regions longer than 100 (right) are
binned in 100 residues. The tick labels indicate the lower bound which is included. Gray bars refer to the previous release (DisProt 7).
Figure 2. Distribution of disorder annotation terms. Terms belong to the Disorder Ontology and only those one node away from the ontology root are
shown. Annotation counts for child terms are propagated to parents up to the root. The dark segments correspond to proteins (left) or residues (right) for
which more than one piece of evidence is available. Different ontology aspects (namespaces) are grouped and have different colors.
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future. The new term introduced in DisProt 8, ‘Biological
condensation’ (DO:00040) has been assigned to a total of
20 proteins, 29 regions and 2610 residues. The new ‘elec-
tron cryomicroscopy’ (DO:00128) term, which is a child of
‘crystallography’, covers 34 proteins, 67 regions and 4726
residues.
Darker segments in Figure 2 indicate the fraction of pro-
teins (left plot) and residues (right plot) for which more
than one experimental evidence is available. At the bottom
in orange the distribution of ‘Detection methods’ terms.
‘Proteins’ and ‘residues’ distributions have a similar shape.
‘Crystallography’, which is a parent of ‘missing electron
density’, covers less residues compared to ‘spectrometry’
and ‘optical analysis’, indicating that regions identified with
crystallographic techniques are shorter on average. More-
over, ‘crystallography’ has less residues covered by multi-
ple experimental evidence compared to other techniques. In
general, disorder annotation is well supported with 44.4%
of disordered proteins and 43.2% of the disordered residues
backed by two or more literature references.
DisProt website
The DisProt website has been completely redesigned, im-
proving the user experience, visualization and functionali-
ties. Additionally, a big effort was made to develop the Dis-
Prot Application Programming Interface (API) to enable
users to retrieve a single entry or a region and to perform ad-
vanced searches via RESTful endpoints (URLs). The new
API and distribution formats are extensively documented
in the help page.
Entry page
The entry page is composed of three main sections. On the
top, general information of the protein including name,Dis-
Prot ID, organism, sequence length, MobiDB and UniPro-
tKB accession numbers are provided. On the top right,
it is possible to select the DisProt version and hide/show
ambiguous/obsolete evidence. A download dropdown but-
ton allows saving the whole entry data in JSON, TSV (tab-
separated) or the corresponding sequence in FASTA for-
mat.
A new dynamic feature viewer allows to visualize DisProt
evidence mapped onto sequence. The feature viewer shows
two tracks by default, DisProt consensus and domains, the
latter including Pfam (37) and Gene3D (38) annotation.
DisProt consensus is generated by merging region annota-
tion following the hierarchy of the ontology terms. In the
last step, when merging the four main ontology branches,
priority is given to ‘interaction partner’, ‘structural transi-
tion’, ‘structural state’ and ‘disorder function’, respectively.
The feature viewer can be expanded to see sub tracks
and it is possible to zoom in and out specific regions, cus-
tomize the view and download a high quality image. Region
tooltips are activated on mouse over and provide detailed
information about the corresponding annotation.
Region details are also provided on the bottom of the
page, organized in a dynamic list of boxes. A search box,
which supports regular expressions, allows to filter the list
of regions. The filter is also applied to the feature and se-
quence viewers (right) in real time, for example, by typing
‘nuclear magnetic resonance’ it is possible to select only re-
gion evidence from NMR experiments.
Browsing and searching data
DisProt implements both a database and a BLAST search
(39), both available from the ‘browse’ page. The database
search allows to compose a query against several fields,
which can be combined to meet multiple criteria. All search
fields accept regular expressions, and ‘Free text’ allows to
search against the entire database content. For example, by
searching ‘p53’ in ‘free text’ and ‘homo | mus’ in ‘organism’
will return all human and mouse proteins with the ‘p53’
string somewhere in the corresponding database records
(protein name, annotation reference title, etc.). Query re-
sults are displayed in the table below the search box. Table
columns are customizable and the result can be downloaded
in JSON, TSV or FASTA format.
DisProt API
DisProt provides programmatic access to perform a search
through REpresentational State Transfer (or RESTful)
Web ServiceAPI. A single entry or evidence can be retrieved
by using DisProt or UniProtKB identifiers. Additionally, a
text search against the entire database can be performed
by specifying query fields (name, organism, etc.) directly
as URL parameters in the HTTP request. JSON, TSV and
FASTA formats are supported.
CONCLUSIONS AND FUTURE WORK
In the previous release, DisProt disorder annotations were
polished and major errors were fixed but the number of
newly annotated proteins was limited. In DisProt 8, dis-
order annotations doubled and a robust infrastructure has
been put in place to leverage and accelerate the annotation
process. The database format has been improved to be flex-
ible enough to capture essential information from the liter-
ature but, at the same time, keeping disorder representation
simple and clear. A new disorder ontology has been formal-
ized with the aim of improving maintenance and data ex-
change with core data resources. The new ontology is ver-
sioned and provides a hierarchy to facilitate term traversal.
Article sentences tracking statements about disorder exper-
imental evidence are now captured providing a corpus for
the implementation of new text-mining models. New pro-
tein examples are used as ground-truth to evaluate predic-
tion methods as in the Critical Assessment of Disorder An-
notation (CAID). DisProt long term sustainability is guar-
anteed by the centrality of DisProt in several initiatives in-
volving large communities of bioinformaticians working on
disorder, such as the IDPfun Marie Curie RISE and the
ELIXIR IDP User Community.
ACKNOWLEDGEMENTS
DisProt is a service of the Italian ELIXIR node. Part of this
work was done in the context of an ELIXIR Implementa-
tion Study linked to the ELIXIR Data platform.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz975/5622715 by Sem
m
elw
eis U
niversity user on 29 N
ovem
ber 2019
Nucleic Acids Research, 2019 7
FUNDING
Agencia Nacional de Promocio´n Cientı´fica y Tecnolo´gica
(ANPCyT) of Argentina [PICT-2015/3367, PICT-
2017/1924]; Ministry of Education, Science and Techno-
logical Development of the Republic of Serbia [ON173001];
Vetenskapsra˚det [2016-03798]; Hungarian National Re-
search, Development, and Innovation Office (NKFIH)
[FK-128133]; Italian Ministry of Health Young Investiga-
tor Grant [GR-2011-02347754]; Ministerio de Economı´a y
Competitividad (MINECO) [BIO2016-78310-R]; ICREA
(ICREA-Academia 2015); Fundac¸a˜o para a Cieˆncia e a
Tecnologia (FCT, Portugal); European Regional Devel-
opment Fund [POCI-01-0145-FEDER-031173, POCI-
01-0145-FEDER-029221]; Mexican National Council of
Science and Technology (CONACYT) [215503]; Elixir-GR,
Action ‘Reinforcement of the Research and Innovation
Infrastructure’, Operational Programme ‘Competitiveness,
Entrepreneurship and Innovation’ [NSRF 2014-2020].
co-financed by Greece and the European Union (European
Regional Development Fund); Hungarian Academy of
Sciences [PREMIUM-2017-48]; Carlsberg Distinguished
Fellowship [CF18-0314]; Danmarks Grundforskningsfond
[DNRF125]; National Research, Development and Inno-
vation Office [K-125340]; Research Foundation Flanders
(FWO) [G.0328.16N]; Hungarian Academy of Sciences
[LP2014-18]; OTKA [K108798 and K124670]. This project
has received funding from the European Union’s Horizon
2020 research and innovation programme [778247]. Fund-
ing for open access charge: European Union’s Horizon
2020 research and innovation programme [778247].
Conflict of interest statement.None declared.
REFERENCES
1. Romero,P., Obradovic,Z., Kissinger,C.R., Villafranca,J.E.,
Garner,E., Guilliot,S. and Dunker,A.K. (1998) Thousands of
proteins likely to have long disordered regions. Pac. Symp.
Biocomput., 1998, 437–448.
2. Wright,P.E. and Dyson,H.J. (1999) Intrinsically unstructured
proteins: re-assessing the protein structure-function paradigm. J.
Mol. Biol., 293, 321–331.
3. van der Lee,R., Buljan,M., Lang,B., Weatheritt,R.J.,
Daughdrill,G.W., Dunker,A.K., Fuxreiter,M., Gough,J., Gsponer,J.,
Jones,D.T. et al. (2014) Classification of intrinsically disordered
regions and proteins. Chem. Rev., 114, 6589–6631.
4. Davey,N.E. (2019) The functional importance of structure in
unstructured protein regions. Curr. Opin. Struct. Biol., 56, 155–163.
5. Perdiga˜o,N., Heinrich,J., Stolte,C., Sabir,K.S., Buckley,M.J.,
Tabor,B., Signal,B., Gloss,B.S., Hammang,C.J., Rost,B. et al. (2015)
Unexpected features of the dark proteome. Proc. Natl. Acad. Sci.
U.S.A., 112, 15898–15903.
6. Mistry,J., Coggill,P., Eberhardt,R.Y., Deiana,A., Giansanti,A.,
Finn,R.D., Bateman,A. and Punta,M. (2013) The challenge of
increasing Pfam coverage of the human proteome. Database, 2013,
bat023.
7. Bhowmick,A., Brookes,D.H., Yost,S.R., Dyson,H.J.,
Forman-Kay,J.D., Gunter,D., Head-Gordon,M., Hura,G.L.,
Pande,V.S., Wemmer,D.E. et al. (2016) Finding our way in the dark
proteome. J. Am. Chem. Soc., 138, 9730–9742.
8. Monastyrskyy,B., Kryshtafovych,A., Moult,J., Tramontano,A. and
Fidelis,K. (2014) Assessment of protein disorder region predictions in
CASP10. Proteins, 82(Suppl. 2), 127–137.
9. Necci,M., Piovesan,D., Dosztanyi,Z., Tompa,P. and Tosatto,S.C.E.
(2017) A comprehensive assessment of long intrinsic protein disorder
from the DisProt database. Bioinformatics, 34, 445–452.
10. Tompa,P. (2005) The interplay between structure and function in
intrinsically unstructured proteins. FEBS Lett., 579, 3346–3354.
11. Bartels,T., Choi,J.G. and Selkoe,D.J. (2011) -Synuclein occurs
physiologically as a helically folded tetramer that resists aggregation.
Nature, 477, 107–110.
12. Theillet,F.-X., Binolfi,A., Bekei,B., Martorana,A., Rose,H.M.,
Stuiver,M., Verzini,S., Lorenz,D., van Rossum,M., Goldfarb,D. et al.
(2016) Structural disorder of monomeric -synuclein persists in
mammalian cells. Nature, 530, 45–50.
13. Yang,J., Gao,M., Xiong,J., Su,Z. and Huang,Y. (2019) Features of
molecular recognition of intrinsically disordered proteins via coupled
folding and binding. Protein Sci., 28, 1952–1965.
14. Pricer,R., Gestwicki,J.E. and Mapp,A.K. (2017) From fuzzy to
function: the new frontier of protein-protein interactions. Acc. Chem.
Res., 50, 584–589.
15. Borgia,A., Borgia,M.B., Bugge,K., Kissling,V.M., Heidarsson,P.O.,
Fernandes,C.B., Sottini,A., Soranno,A., Buholzer,K.J., Nettels,D.
et al. (2018) Extreme disorder in an ultrahigh-affinity protein
complex. Nature, 555, 61–66.
16. Keul,N.D., Oruganty,K., Schaper Bergman,E.T., Beattie,N.R.,
McDonald,W.E., Kadirvelraj,R., Gross,M.L., Phillips,R.S.,
Harvey,S.C. and Wood,Z.A. (2018) The entropic force generated by
intrinsically disordered segments tunes protein function. Nature, 563,
584–588.
17. Egger,S., Chaikuad,A., Kavanagh,K.L., Oppermann,U. and
Nidetzky,B. (2011) Structure and mechanism of human UDP-glucose
6-dehydrogenase. J. Biol. Chem., 286, 23877-23887.
18. Piovesan,D., Tabaro,F., Paladin,L., Necci,M., Micetic,I.,
Camilloni,C., Davey,N., Doszta´nyi,Z., Me´sza´ros,B., Monzon,A.M.
et al. (2018) MobiDB 3.0: more annotations for intrinsic disorder,
conformational diversity and interactions in proteins. Nucleic Acids
Res., 46, D471–D476.
19. Me´sza´ros,B., Zeke,A., Reme´nyi,A., Simon,I. and Doszta´nyi,Z. (2016)
Systematic analysis of somatic mutations driving cancer: uncovering
functional protein regions in disease development. Biol. Direct, 11, 23.
20. Babu,M.M. (2016) The contribution of intrinsically disordered
regions to protein function, cellular complexity, and human disease.
Biochem. Soc. Trans., 44, 1185–1200.
21. Ruan,H., Sun,Q., Zhang,W., Liu,Y. and Lai,L. (2019) Targeting
intrinsically disordered proteins at the edge of chaos. Drug Discov.
Today, 24, 217–227.
22. Hu,G., Wu,Z., Wang,K., Uversky,V.N. and Kurgan,L. (2016)
Untapped potential of disordered proteins in current druggable
human proteome. Curr. Drug Targets, 17, 1198–1205.
23. The UniProt Consortium (2019) UniProt: a worldwide hub of protein
knowledge. Nucleic Acids Res., 47, D506–D515.
24. Piovesan,D., Tabaro,F., Micˇetic´,I., Necci,M., Quaglia,F.,
Oldfield,C.J., Aspromonte,M.C., Davey,N.E., Davidovic´,R.,
Doszta´nyi,Z. et al. (2017) DisProt 7.0: a major update of the database
of disordered proteins. Nucleic Acids Res., 45, D1123–D1124.
25. Gouw,M., Michael,S., Sa´mano-Sa´nchez,H., Kumar,M., Zeke,A.,
Lang,B., Bely,B., Chemes,L.B., Davey,N.E., Deng,Z. et al. (2018) The
eukaryotic linear motif resource – 2018 update. Nucleic Acids Res.,
46, D428–D434.
26. Schad,E., Ficho´,E., Pancsa,R., Simon,I., Doszta´nyi,Z. and
Me´sza´ros,B. (2018) DIBS: a repository of disordered binding sites
mediating interactions with ordered proteins. Bioinformatics, 34,
535–537.
27. Ficho´,E., Reme´nyi,I., Simon,I. and Me´sza´ros,B. (2017) MFIB: a
repository of protein complexes with mutual folding induced by
binding. Bioinformatics, 33, 3682–3684.
28. Necci,M., Piovesan,D. and Tosatto,S.C.E. (2018) Where differences
resemble: sequence-feature analysis in curated databases of
intrinsically disordered proteins. Database, 2018.
29. Shin,Y. and Brangwynne,C.P. (2017) Liquid phase condensation in
cell physiology and disease. Science, 357, eaaf4382.
30. Necci,M., Piovesan,D. and Tosatto,S.C.E. (2016) Large-scale analysis
of intrinsic disorder flavors and associated functions in the protein
sequence universe. Protein Sci., 25, 2164–2174.
31. Piovesan,D. and Tosatto,S.C.E. (2019) INGA 2.0: improving protein
function prediction for the dark proteome. Nucleic Acids Res., 47,
W373–W378.
32. Smith,B., Ashburner,M., Rosse,C., Bard,J., Bug,W., Ceusters,W.,
Goldberg,L.J., Eilbeck,K., Ireland,A., Mungall,C.J. et al. (2007) The
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz975/5622715 by Sem
m
elw
eis U
niversity user on 29 N
ovem
ber 2019
8 Nucleic Acids Research, 2019
OBO Foundry: coordinated evolution of ontologies to support
biomedical data integration. Nat. Biotechnol., 25, 1251-1255.
33. Smith,M.K., Welty,C. and McGuinness,D.L. (2004) OWLWeb
Ontology Language Overview.
34. Mottin,L., Gobeill,J., Pasche,E., Michel,P.-A., Cusin,I., Gaudet,P.
and Ruch,P. (2016) neXtA5: accelerating annotation of articles via
automated approaches in neXtProt. Database, 2016,
doi:10.1093/database/bay127.
35. Europe,PMC consortium. (2015) Europe PMC: a full-text literature
database for the life sciences and platform for innovation. Nucleic
Acids Res., 43, D1042–D1048.
36. Linden,M., Prochazka,M., Lappalainen,I., Bucik,D., Vyskocil,P.,
Kuba,M., Sile´n,S., Belmann,P., Sczyrba,A., Newhouse,S. et al. (2018)
Common ELIXIR Service for Researcher Authentication and
Authorisation [version 1; peer review: 3 approved, 1 approved with
reservations]. F1000Research, 7, 1199.
37. El-Gebali,S., Mistry,J., Bateman,A., Eddy,S.R., Luciani,A.,
Potter,S.C., Qureshi,M., Richardson,L.J., Salazar,G.A., Smart,A.
et al. (2019) The Pfam protein families database in 2019. Nucleic
Acids Res., 47, D427–D432.
38. Lewis,T.E., Sillitoe,I., Dawson,N., Lam,S.D., Clarke,T., Lee,D.,
Orengo,C. and Lees,J. (2018) Gene3D: Extensive prediction of
globular domains in proteins. Nucleic Acids Res., 46, D435–D439.
39. Altschul,S.F., Gish,W., Miller,W., Myers,E.W. and Lipman,D.J.
(1990) Basic local alignment search tool. J. Mol. Biol., 215, 403–410.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz975/5622715 by Sem
m
elw
eis U
niversity user on 29 N
ovem
ber 2019
